|
Session
|
Moderator & Panelists
|
Timing
|
|
Breakfast/networking session
|
All attendees
|
8:00 a.m. – 9:00 a.m.
|
|
Welcome and Introduction:
Objectives of the summit
Recap of advisory boards and specific industry proposed solution
Discussion of today’s interactive summit model
Introduction of speaker
|
Confirmed: Dr. Bruce Quinn, Senior Health Policy Advisor, Foley Hoag LLP
|
9:00 a.m. – 9:15 a.m.
|
|
Introductory Speaker:
Challenges facing reimbursement of molecular diagnostics
|
Confirmed: Dr. Reed Tuckson, Executive Vice President and Chief of Medical Affairs, United Health Group
|
9:15 a.m. – 9:45 a.m.
|
|
Panel 1:
Evidentiary standards and data requirements for payer coverage
|
Expert moderator – TBD
Confirmed: Jerry
Conway, Vice President of Reimbursement & Payer Strategy, Foundation
Medicine
Confirmed: Dr. Jeff Allen, PhD, Executive Director, Friends of Cancer Research
Invited: Brian Loy, Market
Medical Officer, Humana
Invited: Dr. Louis Jacques, director of the Division of Items and Devices in the Coverage and Analysis Group, CMS
|
9:45 a.m. – 11:15 a.m.
|
|
Break
|
11:15 am – 11:30 am
|
|
Panel 2:
Becoming the standard of care: Inclusion of new molecular diagnostics into clinical guidelines
|
Expert Moderator – TBD
Confirmed: Joan
McClure, Vice President of Clinical Information and Publications, National Comprehensive Cancer
Network
|
11:30 am – 12:45 pm
|
|
Lunch served & short break
|
12:45 p.m. – 1:15 p.m.
|
|
Luncheon keynote session:
Challenges and future of investing in molecular diagnostics
|
PMC/BIO representative to introduce keynote speaker
|
1:15 p.m. – 1:45 p.m.
20 minutes speech
10 minutes Q&A
|
|
Panel 3:
Issues impacting market access, such as
|
Confirmed: Expert moderator – Dr. Jared Schwartz, Chief Medical
Officer, Aperio
|
1:45 p.m. – 3:15 p.m.
|
|
companion diagnostics
and physician/patient education
|
Confirmed: Andrea Ferris, President of the LUNGevity Foundation
Invited: Kelly Burgeson, Executive Director, Access and Reimbursement, Oncology, Boehringer Ingelheim Pharmaceuticals
Confirmed: Dr. Mike Kolodziej, National Medical Director for Oncology Strategies, Aetna
Confirmed: Dr. Anne- Marie Martin, PhD, Head, Precision Medicine & Diagnostics, GlaxoSmithKline Oncology
|
|
|
Break
|
3:15 p.m. – 3:30 p.m.
|
|
Panel 4:
Incentivizing personalized medicine diagnostic development
|
Expert moderator – Confirmed:
Vicki Seyfert-Margolis, Ph.D., Chief Scientific and Strategy Officer, Precision Health Holdings
Confirmed: Dr. Hawazin Faruki, Vice President of Clinical Development, LabCorp
Confirmed: Mary Dwight, Vice President of Government Affairs,
Cystic Fibrosis Foundation
Confirmed: Dr. Stephen L. Eck, Vice President, Global Head of Medical Oncology, Astellas Pharma Global Development
|
3:30 p.m. – 4:45 p.m.
|
|
Concluding session:
Overview of solutions discussed during today’s summit and next steps
|
PMC/BIO executive
|
4:45 p.m. – 5:00 p.m.
|
|
Reception begins
|
5:00 p.m.
|
